We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Utilizing Rilonacept in Gout Exacerbations (SURGE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00855920
First Posted: March 5, 2009
Last Update Posted: April 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals
  Purpose
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.

Condition Intervention Phase
Acute Gout Flare Drug: Rilonacept Drug: Indomethacin Other: Placebo (for Indomethacin) Other: Placebo (for Rilonacept) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare

Resource links provided by NLM:


Further study details as provided by Regeneron Pharmaceuticals:

Primary Outcome Measures:
  • Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours [ Time Frame: Pre-dose on Day 1 (Baseline); post-dose at 4, 8, 12, 24, 48, 72 hours and then daily up to Day 13 or until gout flare ends ]
    Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain. Change in PAP-LS in the index joint from baseline (Day 1) to the averaged PAP-LS values at 24, 48 and 72 hours was reported in this outcome measure (averaged PAP value= [PAP at 24 hours + PAP at 48 hours + PAP at 72 hours]/3).


Secondary Outcome Measures:
  • Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 72 Hours [ Time Frame: Baseline (Day 1) to 72 hours ]
    Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.

  • Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 48 Hours [ Time Frame: Baseline (Day 1) to 48 hours ]
    Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.

  • Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 24 Hours [ Time Frame: Baseline (Day 1) to 24 hours ]
    Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.


Enrollment: 225
Study Start Date: March 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Placebo (for Rilonacept) and Indomethacin
Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Drug: Indomethacin
Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Other: Placebo (for Rilonacept)
Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
Active Comparator: Rilonacept and Indomethacin
Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Drug: Rilonacept
Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
Drug: Indomethacin
Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Active Comparator: Rilonacept and Placebo (for Indomethacin)
Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
Drug: Rilonacept
Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
Other: Placebo (for Indomethacin)
Placebo (for Indomethacin) orally TID for 12 days.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female 18 - 70 years of age
  2. Previously met the preliminary criteria of ARA for the classification of the acute arthritis of primary gout
  3. Presenting with an acute attack (flare) of gout within 48 hours of pain onset and pain of at least moderate severity
  4. Must have at least 1 on the 0-3 scale for the swelling and the tenderness assessments of the gouty index joint
  5. Current presentation of acute gout flare in 3 joints or less

Exclusion Criteria:

  1. Treatment with any non-steroidal anti-inflammatory drug (NSAIDs) or opiates within 48 hours prior to baseline assessments. Treatment with long-acting NSAIDs within 1 month prior to baseline visit. Treatment with naproxen, meloxicam, nabumetone, celecoxib and indomethacin SR within 5 days prior to baseline visit.
  2. Treatment with oral analgesics within 6 hours before baseline assessments. Treatment with topical analgesics within 12 hours before baseline assessments
  3. History of NSAID intolerance
  4. Participants with history of chronic, gouty arthritis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00855920


  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
Huntsville, Alabama, United States
United States, Arizona
Mesa, Arizona, United States
Phoenix, Arizona, United States
Sierra Vista, Arizona, United States
United States, California
Burbank, California, United States
Whittier, California, United States
United States, Florida
Clearwater, Florida, United States
Debary, Florida, United States
Deland, Florida, United States
Jupiter, Florida, United States
Orange Park, Florida, United States
Orlando, Florida, United States
Oviedo, Florida, United States
United States, Idaho
Boise, Idaho, United States
United States, Kentucky
Elizabethtown, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
Wheaton, Maryland, United States
United States, Michigan
Detroit, Michigan, United States, 48221
Stevenville, Michigan, United States
United States, Montana
Billings, Montana, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Albany, New York, United States
United States, North Carolina
Burlington, North Carolina, United States
Cary, North Carolina, United States
Raleigh, North Carolina, United States, 27612
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
United States, Ohio
Willoughby Hills, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Lake Oswego, Oregon, United States
Portland, Oregon, United States
United States, Pennsylvania
Johnstown, Pennsylvania, United States
Limerick, Pennsylvania, United States
Norristown, Pennsylvania, United States
United States, South Carolina
Greenville, South Carolina, United States
United States, Tennessee
Bristol, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Forth Worth, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
Mesquite, Texas, United States
North Richland Hills, Texas, United States
San Antonio, Texas, United States
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Study Director: Robert Evans, PharmD Regeneron Pharmaceuticals
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00855920     History of Changes
Other Study ID Numbers: IL1T-GA-0814
First Submitted: February 13, 2009
First Posted: March 5, 2009
Results First Submitted: March 20, 2017
Results First Posted: April 28, 2017
Last Update Posted: April 28, 2017
Last Verified: March 2017

Keywords provided by Regeneron Pharmaceuticals:
Metabolism, Inborn Errors
Allopurinol
Metabolic Diseases
Genetic Diseases, Inborn
Musculoskeletal Diseases
Joint Diseases
Arthritis
Rheumatic Diseases
Metabolic disorder
Purine-Pyrimidine Metabolism, Inborn Errors
Gout
Flare

Additional relevant MeSH terms:
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Indomethacin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action